Lapatinib : interactions médicamenteuses

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (notice Colchicine, Interactions médicamenteuses)

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (notice Dabigatran, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (notice Rimégépant, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

• Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus concentrations ( 7.4 , 12.3 ). (notice Sirolimus, Interactions médicamenteuses)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (notice Sofosbuvir et velpatasvir, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (notice Talazoparib, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

Avoid strong CYP3A4 inducers. (notice Lapatinib, Interactions médicamenteuses)

Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (notice Topotécan, Interactions médicamenteuses)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (notice Lapatinib, Mises en garde et précautions)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (notice Vincristine, Interactions médicamenteuses)

Avoid strong CYP3A4 inhibitors. (notice Lapatinib, Interactions médicamenteuses)

P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (notice Afatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. (notice Édoxaban, Interactions médicamenteuses)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (notice Eltrombopag, Interactions médicamenteuses)

Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (notice Emtricitabine et ténofovir, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (notice Fidaxomicine, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

…Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (notice Lomitapide, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

Midazolam : Following coadministration of TYKERB and midazolam (CYP3A4 substrate), 24-hour systemic exposure (AUC) of orally administered midazolam increased 45%, while 24-hour AUC of intravenously administered midazolam increased 22%. (notice Lapatinib, Interactions médicamenteuses)

P-Glycoprotein (P-gp) Inhibitors Clinical Impact: The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. (notice Morphine, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (notice Naldémédine, Interactions médicamenteuses)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. (notice Lapatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (notice Lapatinib, Interactions médicamenteuses)

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (notice Lapatinib, Interactions médicamenteuses)

Lenacapavir (LEN), a component of BIXLENVO, is a moderate inhibitor of CYP3A and a P-gp inhibitor. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (notice Dapagliflozine, Interactions médicamenteuses)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (notice Éribuline, Interactions médicamenteuses)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (notice Lapatinib, Interactions médicamenteuses)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (notice Lapatinib, Interactions médicamenteuses)

Substrates and Inhibitors of P-glycoprotein It has been shown in vitro that mefloquine is a substrate and an inhibitor of P-glycoprotein. (notice Méfloquine, Interactions médicamenteuses)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (notice Lapatinib, Interactions médicamenteuses)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (notice Lapatinib, Interactions médicamenteuses)

Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (notice Silodosine, Interactions médicamenteuses)

Mechanism and Clinical Effect(s) Vepdegestrant is a P-gp inhibitor. (notice Vepdégestrant, Interactions médicamenteuses)